Alnylam Pharmace. buy Subdi
Start price
27.10.18
/
50%
€70.57
Target price
08.11.18
€132.40
Performance (%)
-6.88%
End price
08.11.18
€65.72
Summary
This prediction ended on 08.11.18 with a price of €65.72. With a performance of -6.88%, the BUY prediction by Subdi finished with a loss. Subdi has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.097% | -1.097% | 23.600% | 43.292% |
| iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
| iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
| iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
| iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by Subdi for this prediction
In the thread Alnylam Pharmace. diskutieren
Subdi stimmt der Buy-Einschätzung von Subdi zu
Subdi stimmt am 27.10.2018 der Buy-Einschätzung von Subdi mit dem Kursziel 146,78$ zu.
Überschrift: Subdi stimmt der Buy-Einschätzung von Subdi zu
(Stop Loss Kurs erreicht)
Stopped prediction by Subdi for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€98.87
10.09.18
10.09.18
€132.40
12.09.18
12.09.18
-9.59%
12.09.18
12.09.18
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€110.65
31.08.18
31.08.18
€132.40
06.09.18
06.09.18
-4.71%
06.09.18
06.09.18